Cargando…

Legal access to medications: a threat to Brazil’s public health system?

BACKGROUND: In Brazil, health is fundamental human right guaranteed by the Constitution of 1988, which created the Brazilian Universal Health System (Sistema Único de Saúde - SUS). The SUS provides medications for outpatient care via policy of pharmaceutical assistance (PA) programmes. Despite the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chieffi, Ana Luiza, Barradas, Rita De Cassia Barata, Golbaum, Moisés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517947/
https://www.ncbi.nlm.nih.gov/pubmed/28724420
http://dx.doi.org/10.1186/s12913-017-2430-x
_version_ 1783251392078544896
author Chieffi, Ana Luiza
Barradas, Rita De Cassia Barata
Golbaum, Moisés
author_facet Chieffi, Ana Luiza
Barradas, Rita De Cassia Barata
Golbaum, Moisés
author_sort Chieffi, Ana Luiza
collection PubMed
description BACKGROUND: In Brazil, health is fundamental human right guaranteed by the Constitution of 1988, which created the Brazilian Universal Health System (Sistema Único de Saúde - SUS). The SUS provides medications for outpatient care via policy of pharmaceutical assistance (PA) programmes. Despite the advances in PA policies which include the improvement in access to medications, there has been a significant increase in lawsuits related to health products and services. This study aimed to characterize the medication processes filed between 2010 and 2014 against the Secretary of State for Health of São Paulo (State Health Department of São Paulo - SES/SP), in Brazil, following PA policies. METHODS: This descriptive study used secondary data on medication lawsuits filed against the SES/SP between 2010 and 2014. The data source was the S-Codes computerized system. RESULTS: In the period evaluated, the number of lawsuits filed concerning health-related products increased approximately 63%; requests for medications were predominant. Approximately 30% of the medications involved in court proceedings were supplied via PA programmes. With regard to medications supplied via specialized component, 81.3% were prescribed in disagreement with the protocols published by the Ministry of Health. Insulin glargine was the most requested medication (6.3%), followed by insulin aspart (3.3%). Because there is no scientific evidence that either of these medicines is superior for the treatment of diabetes, neither of them has been incorporated into the SUS by the National Commission for Technology Incorporation. The judicial data showed that most of the lawsuits involved normal proceedings (i.e., individual demands), were filed by private lawyers, and named the State of São Paulo as the sole defendant, demonstrating the individual nature of these claims. The data indicate inequality in the distribution between the number of cases and lawyers and the number of lawsuits and prescribers, evidencing the concentration of lawyers and physicians in filing lawsuits. CONCLUSION: The judicialization of health in the State of São Paulo with the characteristics presented herein is a threat to the SUS.
format Online
Article
Text
id pubmed-5517947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55179472017-08-16 Legal access to medications: a threat to Brazil’s public health system? Chieffi, Ana Luiza Barradas, Rita De Cassia Barata Golbaum, Moisés BMC Health Serv Res Research Article BACKGROUND: In Brazil, health is fundamental human right guaranteed by the Constitution of 1988, which created the Brazilian Universal Health System (Sistema Único de Saúde - SUS). The SUS provides medications for outpatient care via policy of pharmaceutical assistance (PA) programmes. Despite the advances in PA policies which include the improvement in access to medications, there has been a significant increase in lawsuits related to health products and services. This study aimed to characterize the medication processes filed between 2010 and 2014 against the Secretary of State for Health of São Paulo (State Health Department of São Paulo - SES/SP), in Brazil, following PA policies. METHODS: This descriptive study used secondary data on medication lawsuits filed against the SES/SP between 2010 and 2014. The data source was the S-Codes computerized system. RESULTS: In the period evaluated, the number of lawsuits filed concerning health-related products increased approximately 63%; requests for medications were predominant. Approximately 30% of the medications involved in court proceedings were supplied via PA programmes. With regard to medications supplied via specialized component, 81.3% were prescribed in disagreement with the protocols published by the Ministry of Health. Insulin glargine was the most requested medication (6.3%), followed by insulin aspart (3.3%). Because there is no scientific evidence that either of these medicines is superior for the treatment of diabetes, neither of them has been incorporated into the SUS by the National Commission for Technology Incorporation. The judicial data showed that most of the lawsuits involved normal proceedings (i.e., individual demands), were filed by private lawyers, and named the State of São Paulo as the sole defendant, demonstrating the individual nature of these claims. The data indicate inequality in the distribution between the number of cases and lawyers and the number of lawsuits and prescribers, evidencing the concentration of lawyers and physicians in filing lawsuits. CONCLUSION: The judicialization of health in the State of São Paulo with the characteristics presented herein is a threat to the SUS. BioMed Central 2017-07-19 /pmc/articles/PMC5517947/ /pubmed/28724420 http://dx.doi.org/10.1186/s12913-017-2430-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chieffi, Ana Luiza
Barradas, Rita De Cassia Barata
Golbaum, Moisés
Legal access to medications: a threat to Brazil’s public health system?
title Legal access to medications: a threat to Brazil’s public health system?
title_full Legal access to medications: a threat to Brazil’s public health system?
title_fullStr Legal access to medications: a threat to Brazil’s public health system?
title_full_unstemmed Legal access to medications: a threat to Brazil’s public health system?
title_short Legal access to medications: a threat to Brazil’s public health system?
title_sort legal access to medications: a threat to brazil’s public health system?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517947/
https://www.ncbi.nlm.nih.gov/pubmed/28724420
http://dx.doi.org/10.1186/s12913-017-2430-x
work_keys_str_mv AT chieffianaluiza legalaccesstomedicationsathreattobrazilspublichealthsystem
AT barradasritadecassiabarata legalaccesstomedicationsathreattobrazilspublichealthsystem
AT golbaummoises legalaccesstomedicationsathreattobrazilspublichealthsystem